Current disclosures include early drug product services at Longmont, including preformulation, FIH capsules and bottles, immediate-release, and enteric or extended-release products. The Mirabel/Whippany drug product businesses were sold in 2023, so their historical commercial network is excluded.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Current disclosures include early drug product services at Longmont, including preformulation, FIH capsules and bottles, immediate-release, and enteric or extended-release products. The Mirabel/Whippany drug product businesses were sold in 2023, so their historical commercial network is excluded.
On 2023-11-02 the company announced completion of the sale of its Mirabel and Whippany drug product businesses. See current service pages for Longmont's early development capabilities.
The solid-state service page integrates screening with subsequent crystallization process development and identifies Edinburgh as a solid-form screening facility.
Program / service
Target / indication
Representative stage
Evidence & scope
Formulation development capabilities
Defined by the client project · Defined by the client project
Services / platform
Service capability does not establish efficacy in humans
Solid-state R&D capabilities
Determined by the submitted sample and research question · Not applicable; service capability
Services / platform
Not applicable; not a human clinical program
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Phillips Medisize announced an investment to acquire the complete footprint of its Chippenham site in England, strengthening its Global Inhalation Center of Excellence alongside Cambridge. Building on the 2025 Vectura acquisition, the site supports drug-device formulation development and early- and late-stage clinical supplies. The announcement links the investment to anticipated growth in complex inhaled therapies.
PharmAla signed an agreement with Corealis Pharma for ALA-002 drug-product development and GMP clinical supply. Corealis has begun formulation work in Laval, Québec, with an initial 50 mg capsule planned. Manufacturing of the first GMP batch is conditional on completing development activities. The agreement establishes a development and supply arrangement, rather than a product approval.
Crystal Pharmatech’s November 4 announcement confirms ED-1 service in Suzhou. Its service page describes integration with solid-form screening for small crystals and pharmaceutical solid forms.
Execution sites, current equipment capacity, technology transfer, and the available scope of GMP services require confirmation.
Public sources confirm service availability. Sample suitability, scope of work, pricing, turnaround time, success criteria, and the quality system require direct confirmation.
This record describes service capabilities, not the clinical progress of a drug candidate or an independent validation of service success rates.
